Cassipa (buprenorphine and naloxone) sublingual film delivers a new dosage for the treatment of opioid dependence.
Cassipa (buprenorphine and naloxone) sublingual film delivers a new dosage for the treatment of opioid dependence.
The FDA recently approved drugs to treat opioid dependence, migraines, and rheumatoid arthritis.
A newly released draft guidance encourages the development of more sustained-release buprenorphine products.
